COLLABORATION AND CLINICAL TRIAL AGREEMENTCollaboration and Clinical Trial Agreement • February 28th, 2020 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and Clinical Trial Agreement (the “Agreement”) is entered into on December 20, 2019 (the “Effective Date”) between 3D Medicines (Beijing) Co., Ltd., a company organized and existing under the laws of P.R.China and having its registered address at Suite 1201,Block B, Yicheng Fortune Center ,22 Ronghua Middle Road, BDA, Beijing, P.R. China (“3DMed”) Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a company organized and existing under the laws of P.R. China and having its registered address at Building C23, 218 Xinghu Street, Suzhou, Jiangsu, P.R. China 215125 (“Jiangsu Alphamab”) (Jiangsu Alphamab and 3DMed collectively, “3DAlpha”), and Tracon Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA (“Tracon”). Tracon, 3D, and Alphamab are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
